American CryoStem Corporation, headquartered in Eatontown, New Jersey, was founded with a mission to advance adipose tissue-based cell technologies. The company focuses on clinical processing, commercial bio-banking, and the development of applications for adipose tissue and autologous adipose-derived regenerative cells (ADRCs). Their services cater to the medical and biotechnology sectors, aiming to provide innovative solutions for regenerative medicine and personalized healthcare.
Notable figures associated with American CryoStem include Agustin Legido, MD, PhD, MBA, who serves on the advisory board. The company has achieved significant milestones, such as receiving FDA approval for an IND to commence a Phase I clinical trial for Long COVID/Post-Acute Sequelae of SARS-CoV-2 (PASC) and initiating a Phase I clinical trial for post-concussion syndrome. These achievements underscore their impact on advancing regenerative medicine and contributing to critical medical research.
